186 related articles for article (PubMed ID: 34144649)
1. Antipsychotic-induced supersensitivity - A reappraisal.
Lugg W
Aust N Z J Psychiatry; 2022 May; 56(5):437-444. PubMed ID: 34144649
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy.
Chouinard G; Samaha AN; Chouinard VA; Peretti CS; Kanahara N; Takase M; Iyo M
Psychother Psychosom; 2017; 86(4):189-219. PubMed ID: 28647739
[TBL] [Abstract][Full Text] [Related]
3. Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis.
Takase M; Kimura H; Kanahara N; Nakata Y; Iyo M
J Psychopharmacol; 2020 May; 34(5):540-547. PubMed ID: 31961236
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic-evoked dopamine supersensitivity.
Servonnet A; Samaha AN
Neuropharmacology; 2020 Feb; 163():107630. PubMed ID: 31077727
[TBL] [Abstract][Full Text] [Related]
5. Recent Discussions on Dopamine Supersensitivity Psychosis: Eight Points to Consider When Diagnosing Treatment-Resistant Schizophrenia.
Kanahara N; Kimura H; Oda Y; Ito F; Iyo M
Curr Neuropharmacol; 2021; 19(12):2214-2226. PubMed ID: 33550976
[TBL] [Abstract][Full Text] [Related]
6. Alterations of Dopamine D2 Receptors and Related Receptor-Interacting Proteins in Schizophrenia: The Pivotal Position of Dopamine Supersensitivity Psychosis in Treatment-Resistant Schizophrenia.
Oda Y; Kanahara N; Iyo M
Int J Mol Sci; 2015 Dec; 16(12):30144-63. PubMed ID: 26694375
[TBL] [Abstract][Full Text] [Related]
7. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors.
Seeman P
CNS Neurosci Ther; 2011 Apr; 17(2):118-32. PubMed ID: 20560996
[TBL] [Abstract][Full Text] [Related]
8. Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review.
Yin J; Barr AM; Ramos-Miguel A; Procyshyn RM
Curr Neuropharmacol; 2017; 15(1):174-183. PubMed ID: 27264948
[TBL] [Abstract][Full Text] [Related]
9. Dopamine supersensitivity psychosis in schizophrenia: Concepts and implications in clinical practice.
Nakata Y; Kanahara N; Iyo M
J Psychopharmacol; 2017 Dec; 31(12):1511-1518. PubMed ID: 28925317
[TBL] [Abstract][Full Text] [Related]
10. Dopamine D2 receptors as treatment targets in schizophrenia.
Seeman P
Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):56-73. PubMed ID: 20643630
[TBL] [Abstract][Full Text] [Related]
11. Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis.
Iyo M; Tadokoro S; Kanahara N; Hashimoto T; Niitsu T; Watanabe H; Hashimoto K
J Clin Psychopharmacol; 2013 Jun; 33(3):398-404. PubMed ID: 23609386
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs for antipsychotic-induced tardive dyskinesia: investigational drugs in Phase II and Phase III clinical trials.
Lockwood JT; Remington G
Expert Opin Emerg Drugs; 2015 Sep; 20(3):407-21. PubMed ID: 26166007
[TBL] [Abstract][Full Text] [Related]
13. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
Chouinard G; Jones BD
Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
[TBL] [Abstract][Full Text] [Related]
14. A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis.
Fallon P; Dursun SM
J Psychopharmacol; 2011 Jun; 25(6):755-62. PubMed ID: 20147573
[TBL] [Abstract][Full Text] [Related]
15. "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time.
Samaha AN; Seeman P; Stewart J; Rajabi H; Kapur S
J Neurosci; 2007 Mar; 27(11):2979-86. PubMed ID: 17360921
[TBL] [Abstract][Full Text] [Related]
16. Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
Takao N; Murai T; Fujiwara H
BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33849886
[TBL] [Abstract][Full Text] [Related]
17. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
Simon N; Azorin JM
Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
[TBL] [Abstract][Full Text] [Related]
18. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
19. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse.
Moncrieff J
Acta Psychiatr Scand; 2006 Jul; 114(1):3-13. PubMed ID: 16774655
[TBL] [Abstract][Full Text] [Related]
20. Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.
Chouinard G
Schizophr Res; 1991; 5(1):21-33. PubMed ID: 1677263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
